GlassScriptPhysician profile
Gabriel Zada
NPI 1871768556
$194,058.86
in general payments reported to CMS, 2019-2025
13 companies · $6,119 in 2025
The $6,119 reported for 2025 was more than what 82% of Neurological Surgery providers received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $71K · 2020: $5,499 · 2021: $15K · 2022: $40K · 2023: $57K · 2024: $69.31 · 2025: $6,119.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $52K · Travel and Lodging: $10K · Food and Beverage: $824.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $51,745.00 |
| Travel and Lodging | $10,250.62 |
| Food and Beverage | $823.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $171,540.26 | 2019-2025 | Core, Sonopet Iq, Nico Brainpath |
| Nico Corporation | $7,579.31 | 2019-2021 | |
| Medtronic, INC. | $4,550.00 | 2021 | |
| Integra Lifesciences Corporation | $3,942.56 | 2021-2022 | |
| Elekta, INC. | $2,002.67 | 2019-2022 | |
| Karl Storz Endoscopy-America | $2,000.00 | 2020 | |
| Osteomed LLC | $1,679.35 | 2019-2021 | |
| Medtronic USA, INC. | $230.19 | 2019 | |
| Viseon, INC. | $187.27 | 2022-2023 | Maxview System - Lateral Set |
| Monteris Medical Corporation | $118.67 | 2025 | Neuroblate |
| Zimmer Biomet Holdings, INC. | $114.86 | 2021 | |
| Leica Microsystems INC. | $113.72 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$4,413,855.59 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gabriel Zada listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.